Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Glenmark Pharmaceuticals is currently trading at Rs 939.50, up by 10.10 points or 1.09% from its previous closing of Rs 929.40 on the BSE.
The scrip opened at Rs 948.00 and has touched a high and low of Rs 953.45 and Rs 930.50 respectively. So far 78,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs. 993.00 on 01-Nov-2016 and a 52 week low of Rs 671.50 on 12-Feb-2016.
Last one week high and low of the scrip stood at Rs 954.00 and Rs 894.10 respectively. The current market cap of the company is Rs 26566 crore.
The promoters holding in the company stood at 46.49%, while Institutions and Non-Institutions held 41.61% and 11.91% respectively.
Glenmark Pharmaceuticals (GPL), has unveiled its Strategic Blueprint to transition into an Innovation?led Global Pharmaceutical Organization over the next decade. The Blueprint conveys the company’s greater business alignment expanding generics to prioritizing research and development efforts in three key therapeutic areas: oncology, respiratory and dermatology.
The innovative oncology pipeline, with candidates targeting multiple tumors, is the top priority with the greater promise to deliver novel, first?in?class molecules and help company evolve into a fully commercialized, innovation?led pharmaceutical company. The strategic blueprint also outlines aggressive plans to increase company’s presence worldwide by strengthening focus on complex generics including injectables, expanding its manufacturing footprint (growing from two formulation facilities to 17).
Glenmark’s current portfolio consists of 109 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1462.50 |
| Dr. Reddys Lab | 5784.50 |
| Cipla | 1451.25 |
| Zydus Lifesciences | 1001.15 |
| Lupin | 1587.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
